Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations.

@article{Webster2017DevelopmentOA,
  title={Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations.},
  author={Lucy Webster and Derek Groskreutz and Anna Grinbergs-Saull and Robert Howard and John T. O'Brien and Gail A. Mountain and Sube Banerjee and Bob Woods and Robert Perneczky and Louise Lafortune and Charlotte Roberts and Jenny McCleery and James Pickett and Frances Bunn and David J Challis and Georgina Charlesworth and Katie Featherstone and Chris Fox and Claire Goodman and R. W. A. Jones and Sarah E Lamb and Esme Moniz-Cook and Justine Schneider and Sasha Shepperd and Claire A Surr and Jo Thompson-Coon and Clive G. Ballard and Carol Brayne and {\'O}rlaith Burke and Alistair S. Burns and Linda Clare and Peter Garrard and Patrick Gavin Kehoe and Peter Anthony Passmore and Clive Holmes and Ian D Maidment and Fliss E. M. Murtagh and Louise Robinson and Gill Livingston},
  journal={Health technology assessment},
  year={2017},
  volume={21 26},
  pages={
          1-192
        }
}
BACKGROUND There is currently no disease-modifying treatment available to halt or delay the progression of the disease pathology in dementia. An agreed core set of the best-available and most appropriate outcomes for disease modification would facilitate the design of trials and ensure consistency across disease modification trials, as well as making results comparable and meta-analysable in future trials. OBJECTIVES To agree a set of core outcomes for disease modification trials for mild to… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 471 references

New standards in Alzheimer’s disease trial design

  • TE Zoda
  • Therapeutics J Clin Studies 2014;6:44–5
  • 2017

Clinical, VU University Medical Center. NCT02389413 Safety and Tolerability of PQ912 in Subjects With Early Alzheimer’s Disease (SAPHIR). 2016

  • A Probiodrug, Julius
  • URL: https://clinicaltrials.gov/ ct2/show…
  • 2016

Development, LLC. NCT02406027 An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer’s Disease Spectrum. 2016

  • Janssen Research
  • URL: https://clinicaltrials.gov/ct2/show…
  • 2016

Similar Papers

Loading similar papers…